Achieve Life Sciences (ACHV) Price & Analysis

Compare

1,687 Followers

ACHV Stock Chart & Stats

$5.00

-$0.11(-3.08%)

At close: Jan 08 4:00 PM EST

$5.00

-$0.11(-3.08%)

Day’s Range― - ―

52-Week Range$1.84 - $5.31

Previous CloseN/A

Volume131.37K

Average Volume (3M)1.45M

Market Cap

$255.52M

Enterprise Value$32.95M

Total Cash (Recent Filing)$55.40M

Total Debt (Recent Filing)$9.96M

Price to Earnings (P/E)―

Beta1.50

Next Earnings

Nov 06, 2025

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.37

Shares Outstanding51,104,970

10 Day Avg. Volume2,621,682

30 Day Avg. Volume1,452,001

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.13

Enterprise Value/Revenue144.52

Enterprise Value/Gross Profit-10.98K

Enterprise Value/Ebitda-0.67

Forecast

1Y Price Target

$14.60

Price Target Upside192.00% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyCytisinicline nearly doubled quit rates compared to placebo in a prior trial focused on e-cigarette users, demonstrating strong tolerability and adherence.

Market OpportunityCytisinicline is expected to penetrate a U.S. market dominated by generics with limited promotion and underutilization.

Regulatory ApprovalCytisinicline received one of the Commissioner's National Priority Vouchers for nicotine vaping addiction, which provides faster review times and more communication with the FDA.

Bears Say

Commercial RisksRisks to the thesis include commercial execution risk, clinical trial risk, regulatory risk, financing risk, and the potential need for a partner.

Regulatory ChallengesThe FDA program provides faster review, increased communication between sponsors and the FDA, a team-based evaluation process, and the potential for accelerated approval when criteria are met.

Achieve Life Sciences News

Achieve Life Sciences appoints Atkisson as Chief Legal Officer

Achieve Life Sciences (ACHV) announced the appointment of Erik Atkisson as Chief Legal Officer. In his new role,...

2d ago

ACHV

Morning Movers: Regional banks in focus after reporting Q3 results

Stock futures are mixed in early trading amid growing concerns over regional banks’ exposure to bad loans and...

5d ago

AXP

Achieve Life Sciences receives FDA CNPV for cytisinicline

Achieve Life Sciences (ACHV) announced that the U.S. Food and Drug Administration has awarded the company a Commissioner’s...

5d ago

ACHV

Achieve Life Sciences announces publication of data on cytisinicline

Achieve Life Sciences (ACHV) announced the publication of new data in Thorax demonstrating that cytisinicline significantly improved smoking...

30d ago

ACHV

Achieve Life Sciences: Promising Prospects in Vaping Addiction Treatment with Cytisinicline

Brandon Folkes, an analyst from H.C. Wainwright, maintained the Buy rating on Achieve Life Sciences. The associated price...

5d ago

ACHV

Achieve Life Sciences Announces Leadership Change

Achieve Life Sciences ( ($ACHV) ) has provided an update. On September 11, 2025, Achieve Life Sciences announced...

14d ago

ACHV

Achieve Life Sciences’ Cytisinicline: A Promising Smoking Cessation Therapy with Strong Market Potential

H.C. Wainwright analyst Brandon Folkes maintained a Buy rating on Achieve Life Sciences today and set a price...

30d ago

ACHV

Achieve Life Sciences promotes Craig Donnelly to Chief Operations Officer

Achieve Life Sciences (ACHV) announced the promotion of Craig Donnelly to Chief Operations Officer. Donnelly has been with...

1M ago

ACHV

Achieve Life Sciences Announces Leadership Change

Achieve Life Sciences ( ($ACHV) ) just unveiled an announcement. On September 5, 2025, Achieve Life Sciences announced...

1M ago

ACHV

Achieve Life Sciences names Mark Rubinstein interim CMO

Achieve Life Sciences (ACHV) announced Mark Rubinstein, M.D., will assume the role of Interim Chief Medical Officer. Rubinstein...

1M ago

ACHV

Promising Outlook for Achieve Life Sciences: Buy Rating Backed by Cytisinicline’s FDA Progress and Market Potential

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Achieve Life Sciences, retaining the price target...

2M ago

ACHV

Buy Rating for Achieve Life Sciences: Strong Market Potential for Cytisinicline with FDA Approval Anticipated

Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Achieve Life Sciences and keeping the price target...

2M ago

ACHV

Achieve Life Sciences announces FDA acceptance of cytisinicline NDA

Achieve Life Sciences (ACHV) announced that the U.S. Food and Drug Administration, FDA, has accepted the cytisinicline New...

2M ago

ACHV

Achieve Life Sciences initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Achieve Life Sciences (ACHV) with a Buy rating and $12 price target The...

2M ago

ACHV

ACHV FAQ

What was Achieve Life Sciences Inc’s price range in the past 12 months?

Achieve Life Sciences Inc lowest stock price was $1.84 and its highest was $5.31 in the past 12 months.

What is Achieve Life Sciences Inc’s market cap?

Achieve Life Sciences Inc’s market cap is $255.52M.

When is Achieve Life Sciences Inc’s upcoming earnings report date?

Achieve Life Sciences Inc’s upcoming earnings report date is Nov 06, 2025 which is in 15 days.

How were Achieve Life Sciences Inc’s earnings last quarter?

Achieve Life Sciences Inc released its earnings results on Aug 07, 2025. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.366 by -$0.004.

Is Achieve Life Sciences Inc overvalued?

According to Wall Street analysts Achieve Life Sciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Achieve Life Sciences Inc pay dividends?

Achieve Life Sciences Inc does not currently pay dividends.

What is Achieve Life Sciences Inc’s EPS estimate?

Achieve Life Sciences Inc’s EPS estimate is -0.24.

How many shares outstanding does Achieve Life Sciences Inc have?

Achieve Life Sciences Inc has 51,104,970 shares outstanding.

What happened to Achieve Life Sciences Inc’s price movement after its last earnings report?

Achieve Life Sciences Inc reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.366. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Achieve Life Sciences Inc?

Currently, no hedge funds are holding shares in ACHV

Achieve Life Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-120.11%

Trailing 12-Months

Asset Growth

-9.04%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Achieve Life Sciences Inc

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Achieve Life Sciences (ACHV) Earnings & Revenues

Historic Earnings Reports

ACHV Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant advancements in regulatory submissions, strategic partnerships, and capital acquisition, indicating strong progress toward commercialization. However, the extended timeline to launch and potential pricing challenges present notable hurdles.View all ACHV earnings summaries

ACHV Stock 12 Month Forecast

Average Price Target

$14.60

▲(192.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.1,4.4,5.699999999999999,7,8.299999999999999,9.6,10.899999999999999,12.199999999999998,13.499999999999998,14.799999999999999,16.099999999999998,17.4,18.7,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.1,3.9846153846153847,4.86923076923077,5.753846153846154,6.638461538461538,7.523076923076923,8.407692307692308,9.292307692307691,10.176923076923076,11.061538461538461,11.946153846153846,12.83076923076923,13.715384615384615,{"y":14.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.1,3.6307692307692307,4.161538461538462,4.6923076923076925,5.223076923076923,5.753846153846154,6.284615384615385,6.815384615384616,7.346153846153847,7.876923076923077,8.407692307692308,8.938461538461539,9.46923076923077,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.71,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >